| Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ... Cell 165 (1), 35-44, 2016 | 3203 | 2016 |
| Mutations associated with acquired resistance to PD-1 blockade in melanoma JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ... New England Journal of Medicine 375 (9), 819-829, 2016 | 3121 | 2016 |
| Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... Cancer discovery 7 (2), 188-201, 2017 | 1221 | 2017 |
| Causes, consequences, and reversal of immune system aging E Montecino-Rodriguez, B Berent-Maoz, K Dorshkind The Journal of clinical investigation 123 (3), 958-965, 2013 | 908 | 2013 |
| Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ... Cell 183 (3), 818-834. e13, 2020 | 407 | 2020 |
| Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017; 7: 188–201. doi: 10.1158/2159-8290 DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... CD-16-1223.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 250 | |
| Immunotherapy resistance by inflammation-induced dedifferentiation A Mehta, YJ Kim, L Robert, J Tsoi, B Comin-Anduix, B Berent-Maoz, ... Cancer discovery 8 (8), 935-943, 2018 | 159 | 2018 |
| Overcoming genetically based resistance mechanisms to PD-1 blockade DY Torrejon, G Abril-Rodriguez, AS Champhekar, J Tsoi, KM Campbell, ... Cancer discovery 10 (8), 1140-1157, 2020 | 123 | 2020 |
| PAK4 inhibition improves PD-1 blockade immunotherapy G Abril-Rodriguez, DY Torrejon, W Liu, JM Zaretsky, TS Nowicki, J Tsoi, ... Nature Cancer 1 (1), 46-58, 2020 | 122 | 2020 |
| Human Mast Cell Activation by Staphylococcus aureus: Interleukin-8 and Tumor Necrosis Factor Alpha Release and the Role of Toll-Like Receptor 2 and CD48 … CM Rocha-de-Souza, B Berent-Maoz, D Mankuta, AE Moses, ... Infection and immunity 76 (10), 4489-4497, 2008 | 112 | 2008 |
| A pilot trial of the combination of transgenic NY-ESO-1–reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab TS Nowicki, B Berent-Maoz, G Cheung-Lau, RR Huang, X Wang, J Tsoi, ... Clinical Cancer Research 25 (7), 2096-2108, 2019 | 88 | 2019 |
| Distinct genetic networks orchestrate the emergence of specific waves of fetal and adult B-1 and B-2 development E Montecino-Rodriguez, M Fice, D Casero, B Berent-Maoz, CL Barber, ... Immunity 45 (3), 527-539, 2016 | 76 | 2016 |
| Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer Y Zhu, DJ Smith, Y Zhou, YR Li, J Yu, D Lee, YC Wang, S Di Biase, ... Cell Stem Cell 25 (4), 542-557. e9, 2019 | 70 | 2019 |
| Are we ready to downregulate mast cells? L Karra, B Berent-Maoz, M Ben-Zimra, F Levi-Schaffer Current opinion in immunology 21 (6), 708-714, 2009 | 68 | 2009 |
| Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a I Bachelet, A Munitz, B Berent-Maoz, D Mankuta, F Levi-Schaffer The Journal of Immunology 180 (9), 6064-6069, 2008 | 66 | 2008 |
| Human mast cells undergo TRAIL-induced apoptosis B Berent-Maoz, AM Piliponsky, I Daigle, HU Simon, F Levi-Schaffer The Journal of Immunology 176 (4), 2272-2278, 2006 | 61 | 2006 |
| CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma SM Larson, CM Walthers, B Ji, SN Ghafouri, J Naparstek, J Trent, ... Cancer discovery 13 (3), 580-597, 2023 | 56 | 2023 |
| Fibroblast growth factor-7 partially reverses murine thymocyte progenitor aging by repression of Ink4a B Berent-Maoz, E Montecino-Rodriguez, RAJ Signer, K Dorshkind Blood, The Journal of the American Society of Hematology 119 (24), 5715-5721, 2012 | 50 | 2012 |
| Proteolytic histone modification by mast cell tryptase, a serglycin proteoglycan-dependent secretory granule protease FR Melo, F Vita, B Berent-Maoz, F Levi-Schaffer, G Zabucchi, G Pejler Journal of Biological Chemistry 289 (11), 7682-7690, 2014 | 48 | 2014 |
| Genetic regulation of thymocyte progenitor aging B Berent-Maoz, E Montecino-Rodriguez, K Dorshkind Seminars in immunology 24 (5), 303-308, 2012 | 23 | 2012 |
Ariel MunitzDepartment of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv UniversityVerified email at post.tau.ac.il
